Avadel Pharmaceuticals Stock (NASDAQ:AVDL)
Previous Close
$10.71
52W Range
$10.41 - $19.09
50D Avg
$13.34
200D Avg
$15.19
Market Cap
$1.03B
Avg Vol (3M)
$1.11M
Beta
1.63
Div Yield
-
AVDL Company Profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
AVDL Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ALKS | Alkermes plc |
| IRWD | Ironwood Pharmaceuticals, Inc. |
| ANIP | ANI Pharmaceuticals, Inc. |
| NBIX | Neurocrine Biosciences, Inc. |
| DVAX | Dynavax Technologies Corporation |
| EGRX | Eagle Pharmaceuticals, Inc. |
| ITCI | Intra-Cellular Therapies, Inc. |
| ACRX | Talphera, Inc. |
| DCPH | Deciphera Pharmaceuticals, Inc. |
| AGRX | Agile Therapeutics, Inc. |
| EVOK | Evoke Pharma, Inc. |
| AMRX | Amneal Pharmaceuticals, Inc. |
| AQST | Aquestive Therapeutics, Inc. |
| ASRT | Assertio Holdings, Inc. |